Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Abstract We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naoki Kawagishi, Goki Suda, Megumi Kimura, Osamu Maehara, Ren Yamada, Yoshimasa Tokuchi, Akinori Kubo, Takashi Kitagataya, Taku Shigesawa, Kazuharu Suzuki, Masatsugu Ohara, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Naoya Sakamoto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9f05ad0e9c3c4bdcaf4b034a07202f1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f05ad0e9c3c4bdcaf4b034a07202f1e
record_format	dspace
spelling	oai:doaj.org-article:9f05ad0e9c3c4bdcaf4b034a07202f1e2021-12-02T17:39:31ZBaseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C10.1038/s41598-021-88632-72045-2322https://doaj.org/article/9f05ad0e9c3c4bdcaf4b034a07202f1e2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88632-7https://doaj.org/toc/2045-2322Abstract We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy.Naoki KawagishiGoki SudaMegumi KimuraOsamu MaeharaRen YamadaYoshimasa TokuchiAkinori KuboTakashi KitagatayaTaku ShigesawaKazuharu SuzukiMasatsugu OharaMasato NakaiTakuya ShoMitsuteru NatsuizakaKenichi MorikawaKoji OgawaYusuke KudoMutsumi NishidaNaoya SakamotoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Naoki Kawagishi Goki Suda Megumi Kimura Osamu Maehara Ren Yamada Yoshimasa Tokuchi Akinori Kubo Takashi Kitagataya Taku Shigesawa Kazuharu Suzuki Masatsugu Ohara Masato Nakai Takuya Sho Mitsuteru Natsuizaka Kenichi Morikawa Koji Ogawa Yusuke Kudo Mutsumi Nishida Naoya Sakamoto Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
description	Abstract We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy.
format	article
author	Naoki Kawagishi Goki Suda Megumi Kimura Osamu Maehara Ren Yamada Yoshimasa Tokuchi Akinori Kubo Takashi Kitagataya Taku Shigesawa Kazuharu Suzuki Masatsugu Ohara Masato Nakai Takuya Sho Mitsuteru Natsuizaka Kenichi Morikawa Koji Ogawa Yusuke Kudo Mutsumi Nishida Naoya Sakamoto
author_facet	Naoki Kawagishi Goki Suda Megumi Kimura Osamu Maehara Ren Yamada Yoshimasa Tokuchi Akinori Kubo Takashi Kitagataya Taku Shigesawa Kazuharu Suzuki Masatsugu Ohara Masato Nakai Takuya Sho Mitsuteru Natsuizaka Kenichi Morikawa Koji Ogawa Yusuke Kudo Mutsumi Nishida Naoya Sakamoto
author_sort	Naoki Kawagishi
title	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
title_short	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
title_full	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
title_fullStr	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
title_full_unstemmed	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
title_sort	baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis c
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9f05ad0e9c3c4bdcaf4b034a07202f1e
work_keys_str_mv	AT naokikawagishi baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT gokisuda baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT megumikimura baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT osamumaehara baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT renyamada baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT yoshimasatokuchi baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT akinorikubo baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT takashikitagataya baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT takushigesawa baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT kazuharusuzuki baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT masatsuguohara baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT masatonakai baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT takuyasho baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT mitsuterunatsuizaka baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT kenichimorikawa baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT kojiogawa baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT yusukekudo baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT mutsuminishida baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc AT naoyasakamoto baselineelevatedserumangiopoietin2predictslongtermnonregressionofliverfibrosisafterdirectactingantiviraltherapyforhepatitisc
_version_	1718379839113658368

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Ejemplares similares